University College London-ko ikertzaileekin lankidetzan egindako argitalpenak (7)

2022

  1. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

    Kidney International, Vol. 101, Núm. 1, pp. 174-184

  2. The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review

    Diabetes Therapy, Vol. 13, Núm. 5, pp. 847-872

  3. The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review

    Diabetes Therapy

2021

  1. Effects of dapagliflozin in stage 4 chronic kidney disease

    Journal of the American Society of Nephrology, Vol. 32, Núm. 9, pp. 2352-2361

2020

  1. Rationale and protocol of the Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

    Nephrology Dialysis Transplantation, Vol. 35, Núm. 2, pp. 274-282

  2. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 35, Núm. 10, pp. 1700-1711

2018

  1. Different rates of progression and mortality in patients with chronic kidney disease at outpatient nephrology clinics across Europe

    Kidney International, Vol. 93, Núm. 6, pp. 1432-1441